Clinical Trials · NCT07832799

Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

Name: Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Not Yet Recruiting
Sponsor: Amgen
Enrollment: 340
Start date: Oct 2026
Locations: See registry
Primary endpoint: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Maridebart Cafraglutide

View Maridebart-Cafraglutide compound reference